Live Breaking News & Updates on Zeid Kayali|Page 2
Stay updated with breaking news from Zeid kayali. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Gabriel Stargardter May 14 (Reuters) - Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had completed the first patient enrollment and dosing in a late-stage U.S. clinical trial of its experimental COVID-19 treatment. It was the company s latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed company s stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalization soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($850 million) on March 1. ....
Text Size: A+ New Delhi: The Covid-19 pandemic continues to wreak havoc across the world the latest count being more than 16,18,35,227 cases and 33,58,658 deaths. The Centers for Disease Control and Prevention (CDC) in the US announced the lifting of mask-wearing for vaccinated people Thursday leaves epidemiologists surprised and, Cambodia’s Covid red zones go hungry and more. ThePrint brings you some stories from around the world on the pandemic to keep you updated. US guidance on masks leaves epidemiologists surprised When the US’ Centers for Disease Control and Prevention (CDC) announced Thursday that vaccinated Americans no longer needed to wear masks in most places, it came as a surprise to American epidemiologists, reports ....
Reuters Published: 14 May 2021 08:50 AM BdST Updated: 14 May 2021 08:50 AM BdST People walk along at a street, following the outbreak of the coronavirus disease, in Shanghai, China May 10, 2021. REUTERS Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had completed the first patient enrolment and dosing in a late-stage US clinical trial of its experimental COVID-19 treatment. ); } It was the company s latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed company s stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalisation soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($8 ....